The Filing Desk

Senseonics

SENS · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

SENS · Last close · November 19, 2026
$8.90
Value Senseonics yourself

Senseonics' revenue rose 56.9% to $35 million in fiscal 2025. Its operating margin was −193.8%, up from −333.1% a year earlier. Free cash flow was −$60 million. The diluted share count rose 32.5%.

Senseonics Holdings, Inc. Latest fiscal year ended December 31, 2025 10-K filed March 2, 2026 · 0001104659-26-022298 Updated
Revenue
$35M
56.9%
Operating margin
−193.8%
139.2 pts
Net income
−$69M
 
Free cash flow
−$60M
 
Return on equity
−310.7%
506.5 pts
Market cap
$585M
Nov 19 close
P/E
—
Loss: no P/E

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

About these figures. Share counts and per-share figures for earlier years are restated for a stock split (1-for-20), so every year is on today's share basis.

Charts show fiscal years, from the 10-K filings.

What Senseonics does

Senseonics is a medical technology company that makes Eversense, a continuous glucose monitoring (CGM) system for people with diabetes. A small sensor is placed under the skin and measures glucose, a removable transmitter sends the readings to an app, and the app shows real-time glucose data. The Eversense 365 sensor lasts up to twelve months, and the Eversense E3 sensor lasts six months. Senseonics says this compares with seven to 15 days for CGM systems worn on the skin.

Revenue comes from selling Eversense products. Until the end of 2025, its partner Ascensia Diabetes Care had the exclusive right to distribute Eversense worldwide. On December 31, 2025, the two companies signed agreements to move commercial operations back to Senseonics. In January 2026 Senseonics began marketing and distributing Eversense 365 in the United States with its own sales force. Effective January 1, 2026, it is entitled to 100% of the revenue from Eversense sales in Italy, Germany, Spain and Sweden. It expects to launch Eversense 365 in Europe by the second half of 2026.

The company describes itself as in the early stages of commercializing the Eversense brand. It competes with other makers of glucose monitors. As of December 31, 2025, it had 137 full-time employees, and it expects that number to grow as it takes on selling its own products.

Its biggest risks, as it describes them

  • It has lost money since it began, and says there is substantial doubt it can keep operating as a going concern.
  • It may not successfully take commercial responsibility for Eversense back from Ascensia and expand sales in the U.S. and Europe.
  • It competes with larger glucose monitoring makers, and insurers may not cover or fully pay for Eversense.
  • It must build a broad network of providers who insert and remove its implanted sensor.
  • It relies on third parties to make Eversense, so supplier problems could hurt its results.
From Senseonics's annual report on Form 10-K, filed March 2, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

Senseonics lost money in fiscal 2025: a net loss of $69 million.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments1821561107594
Debt incl. finance leases6056413536
Net debt (negative means net cash)−122−100−68−40−58
Net debt to EBITDA—————
Debt to equity——1.1x—0.6x
Interest coverage−3.4x−3.7x−6.8x−8.9x−13.8x
Current ratio7.8x5.1x7.5x2.4x4.8x
Quick ratio7.5x4.9x7.0x2.2x4.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Senseonics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

What Senseonics says to expect

  • Full year 2026: global net revenue and gross marginSenseonics is raising its full-year 2026 global net revenue guidance to $68 million to $70 million from $62 million to $66 million, representing year-over-year growth of 93% to 98%, and is raising its full-year gross margin guidance to more than 60% from its prior range of 58% to 61%.
The company's own words, from its earnings release (Form 8-K, Exhibit 99), filed November 9, 2026. They are its expectations, not ours, and not a forecast or price target from The Filing Desk. Replaced when the next release is out.

Insider trades

Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $627,302 of Senseonics shares on the open market, and none sold any.

Buys and sells by month
US$ millions, open-market purchases (up) and sales (down) by officers, directors and 10% owners in each month.
BoughtSold
DateInsiderTradeSharesPriceValueFiling
Nov 13, 2026Douglas A RoederDirectorBought17,041$10.32$175,860Form 4
Aug 19, 2026Douglas A RoederDirectorBought13,953$8.98$125,300Form 4
May 12, 2026Douglas A RoederDirectorBought22,686$5.56$126,134Form 4
Mar 13, 2026Douglas A RoederDirectorBought17,500$5.73$100,275Form 4
Mar 13, 2026Timothy T GoodnowPresident and CEO, DirectorBought17,225$5.79$99,733Form 4
Open-market purchases and sales by officers, directors and 10% owners, from their Form 4 filings with the SEC: one row per person, day and filing, at the day's average price. Grants, option exercises and shares withheld for tax aren't counted. Insiders buy and sell for many reasons, such as taxes, spreading their savings or a plan set up months earlier, so a trade on its own says little about where a company is heading. For information only, not investment advice. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score4 of 92 of 94 of 9
Rule of 40−278.3%−278.7%−114.0%
Altman Z''−18.25−32.56−24.07
Accruals ratio6.2%−15.2%−8.8%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positiveFailFailFail
Cash from operations is positiveFailFailFail
Return on assets roseFailFailFail
Cash from operations exceeds net incomeFailPassPass
Debt fell relative to assetsPassFailFail
Current ratio rosePassFailPass
Share count didn't risePassFailFail
Gross margin roseFailFailPass
Revenue rose relative to assetsPassPassPass
F-score4 of 92 of 94 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Senseonics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
SenseonicsFY2556.9%−193.8%−170.9%——4
ClearPoint NeuroFY2517.8%−65.4%−66.1%−104.7%—4Compare
CytoSorbentsFY254.1%−39.8%−33.8%———Compare
Orchestra BioMedFY251,169.2%−154.7%−147.7%——5Compare
StereotaxisFY2520.3%−68.3%−42.5%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue06192151416222235
Revenue growth773.7%1,819.6%196.8%12.6%−76.8%176.3%19.9%36.6%0.4%56.9%
Gross profit−0−3−8−19−17−133016
Research and development26313238202740494132
Operating income−42−56−88−131−79−57−69−76−75−68
Net income−44−59−94−116−175−302142−60−79−69
Diluted EPS (US$)−9.80−10.20−12.00−12.20−15.40−14.40−2.20−2.20−2.50−1.66
Diluted shares (millions)4689112131283242
Cash flow
Cash from operations−38−56−91−136−67−56−66−70−60−59
Capital expenditure0011000021
Free cash flow−38−56−92−137−68−56−67−71−63−60
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation24687999910
Balance sheet at fiscal year end
Cash and short-term investments203613796181821561107594
Debt incl. finance leases19241512576056413536
Total assets224616013336199178138100126
Total liabilities273989141177384143657965
Shareholders' equity−5771−9−144−186−336−1761
Margins and ratios
Gross margin−98.8%−53.1%−43.1%−91.3%−350.9%−5.9%16.6%13.8%2.4%44.7%
Operating margin−12,781.0%−883.6%−463.1%−613.4%−1,598.9%−418.1%−418.7%−337.7%−333.1%−193.8%
Net margin−13,231.9%−927.4%−496.9%−542.5%−3,539.5%−2,211.9%867.2%−269.7%−349.8%−196.0%
Free cash flow margin−11,594.9%−880.0%−485.2%−643.6%−1,366.0%−411.6%−406.5%−314.9%−279.0%−170.9%
Rule of 40 (growth + FCF margin)−10,821.2%939.5%−288.4%−631.0%−1,442.8%−235.3%−386.7%−278.3%−278.7%−114.0%
Return on capital——————————
Return on equity——−239.3%−369.1%———−363.6%−817.2%−310.7%
Return on assets−317.2%−173.3%−91.3%−78.9%−207.6%−257.6%75.5%−38.2%−65.9%−61.0%
Net debt to EBITDA——————————
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Senseonics' Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Senseonics.